28,000 Shares in Repligen Corporation $RGEN Acquired by Covea Finance

Covea Finance bought a new stake in Repligen Corporation (NASDAQ:RGEN) during the 4th quarter, Holdings Channel.com reports. The firm bought 28,000 shares of the biotechnology company’s stock, valued at approximately $4,588,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in RGEN. Measured Wealth Private Client Group LLC bought a new position in Repligen during the 3rd quarter worth approximately $29,000. CWM LLC boosted its stake in shares of Repligen by 67.2% in the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 135 shares during the last quarter. Johnson Financial Group Inc. acquired a new stake in shares of Repligen during the third quarter worth $65,000. Trust Co. of Vermont acquired a new stake in shares of Repligen during the third quarter worth $67,000. Finally, Wilmington Savings Fund Society FSB raised its stake in Repligen by 2,750.0% during the third quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock worth $69,000 after buying an additional 495 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Trading Down 3.2%

RGEN opened at $113.88 on Friday. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $175.77. The company has a current ratio of 8.37, a quick ratio of 7.12 and a debt-to-equity ratio of 0.26. The company has a market cap of $6.41 billion, a P/E ratio of 133.98, a price-to-earnings-growth ratio of 2.30 and a beta of 1.14. The company has a fifty day moving average price of $140.22 and a two-hundred day moving average price of $146.51.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The company had revenue of $197.91 million for the quarter, compared to analysts’ expectations of $192.23 million. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The business’s revenue was up 18.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.44 EPS. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Analysts predict that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on RGEN shares. KeyCorp reaffirmed an “overweight” rating on shares of Repligen in a research report on Wednesday, February 25th. Weiss Ratings lowered Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, March 3rd. UBS Group dropped their price objective on Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Barclays cut their target price on Repligen from $200.00 to $175.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Finally, Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and a consensus price target of $174.58.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.